Table 1 Characteristics and outcome of 112 febrile urinary tract infection occurring among patients with neurogenic bladder depending on treatment duration

Number of febrile UTI^a

28

35

49

112

Patient characteristics

 Sex (women/men)

12/16

11/24

9/40

32/80

0.2453

 Age: mean year (SD)

49.6 (20.1)

46.5 (24.7)

31 (19.7)

38.4 (11.7)

0.1443

 Fever: mean °C (SD)

38.6 (0.33)

38.9 (0.76)

39.07 (0.78)

38.8 (0.6)

0.5469

 Neurological deficit N (%)

  Paraplegia

18 (64)

20 (57)

27 (55)

65 (58)

0.2604

  Tetraplegia

5 (18)

2 (6)

13 (27)

20 (18)

0.5205

  Multiple sclerosis

4 (14)

6 (17)

6 (12)

16(14)

0.9299

  Brain injury

1 (4)

7 (20)

3 (6)

11(10)

0.1042

 Voiding management N (%)

  Intermittent cathererization

14 (50)

13 (37.1)

30 (62)

57 (51)

0.4564

  Indwelling catheter

2 (7)

4 (11)

6 (12)

12 (10)

0.9899

  Reflex voiding

7 (25)

8 (23)

7 (14)

22 (19)

0.8349

  Urinary diversion

2 (7)

6 (17)

3 (6)

11 (10)

  Others

3 (11)

4 (11)

3 (6)

10 (10)

Biological variables

 Leukocyte count: median/L (SD)

12. 9 (5.5)

13 (6.9)

12 (5.7)

12.6 (6)

0.4426

 CRP mean mg/l (SD)

140 (84)

139 (89)

122(90)

121 (84)

0.9953

 Positive blood culture N (%)

3 (10)

5 (14)

9 (18)

17 (15)

0.5246

 Microorganism sample N (%)

   E coli

17 (53)

16 (37.2)

22 (33)

55 (49)

   Pseudomonas aeruginosa

6 (18.7)

6 (13.9)

7 (10.6)

19 (13.5)

   Enterococcus

4 (12.5)

7 (16.2)

8 (12)

19 (13.5)

   Klebsiella

2 (6.25)

4 (9.3)

8 (12)

14 (10)

   Proteus

1 (3.12)

3 (7)

4 (6)

8(5.6)

  Others

2 (6.43)

7 (16.4)

17 (26.4))

26 (18.4)

Antibiotic treatment

 Mean treatment duration (SD)

7.9 (2.3)

13.4 (1.9)

27.3 (9.8)

18.1 (10.7)

0.0250

 Mean parenteral treatment duration (median, SD)

8 (8, ±2.2)

6.8 (5, ±5.33)

11.2 (7, ±10.6)

8.2 (6, ±8.3)

 Dual therapy N (%)

17 (61)

18 (52)

34 (70)

69 (62)

0.9669

 Antibiotic treatment N (%)

  Third generation cephalosporin

16 (33)

19 (26.3)

32 (32)

67 (30.6)

  Aminoglycosides

12 (25)

18 (25)

21 (21)

51 (23.2)

  Fluoroquinolones

6 (12.5)

14 (19.4)

16 (16)

36 (16.4)

  Penicillin

9 (18.8)

12 (16.7)

14 (14)

35 (16)

  Carbapenem

4 (8.3)

5 (6.9)

11 (11)

20 (9.1)

  Colimycin

1 (2)

2 (2.8)

2 (2)

5 (2.3)

  Cotrimoxazole

0

0

3 (3)

3 (1.4)

  Fosfomycin

0

2 (2.8)

0

2 (1)

Outcome (1 month)

 Cure N (%)

20 (71.4)

19 (54.2)

28 (57.1)

67 (60.0)

0.3979

 Failure N (%) including:

6 (21.6)

10 (28.5)

15 (30.8)

31 (27.5)

  Persistence of symptoms

5 (17.8)

9 (25.7)

12 (24.4)

26 (23.2)

  Death related to UTI

1 (3.5)

1 (3)

3 (6.1)

5 (4.4)

 Patients who could not be evaluated N (%)^b

2 (7.1)

6 (17.1)

6 (12.2)

14 (12.5)

  Requiring another antibiotic treatment for concomitant infection

0

1

4

5

  Lost to follow up

1

1

1

3

  Death unrelated to UTI

1

4

1

6

 Negative urine culture (D30) N (%)

17 (60.7)

15 (42.8)

21 (42.8)

53 (47.3)

0.635